ArsenalBio
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.
Domain
arsenalbio.com
Country
United StatesIndustry
BiotechnologyEmployees
251-500
Last Funding
$325.0M
Founded
2018
Tech Stack (13 technologies)
Frequently Asked Questions
What technologies does ArsenalBio use?+
ArsenalBio uses 13 technologies including Google Analytics, Google Tag Manager, WordPress.
What industry is ArsenalBio in?+
ArsenalBio operates in the Biotechnology industry.
Where is ArsenalBio based?+
ArsenalBio is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026